首页> 中文期刊> 《世界移植杂志》 >De novo glomerular diseases after renal transplantation:How is it different from recurrent glomerular diseases?

De novo glomerular diseases after renal transplantation:How is it different from recurrent glomerular diseases?

         

摘要

The glomerular diseases after renal transplantation can occur de novo,i.e.,with no relation to the native kidney disease,or more frequently occur as a recurrence of the original disease in the native kidney.There may not be any difference in clinical features and histological pattern between de novo glomerular disease and recurrence of original glomerular disease.However,structural alterations in transplanted kidney add to dilemma in diagnosis.These changes in architecture of histopathology can happen due to:(1) exposure to the immunosuppression specifically the calcineurin inhibitors(CNI);(2) in vascular and tubulointerstitial alterations as a result of antibody mediated or cellmediated immunological onslaught;(3) post-transplant viral infections;(4) ischemia-reperfusion injury; and(5) hyperfiltration injury.The pathogenesis of the de novo glomerular diseases differs with each type.Stimulation of B-cell clones with subsequent production of the monoclonal Ig G,particularly Ig G3 subtype that has higher affinity to the negatively charged glomerular tissue,is suggested to be included in PGNMID pathogenesis.De novo membranous nephropathy canbe seen after exposure to the cryptogenic podocyte antigens.The role of the toxic effects of CNI including tissue fibrosis and the hemodynamic alterations may be involved in the de novo FSGS pathophysiology.The well-known deleterious effects of HCV infection and its relation to MPGN disease are frequently reported.The new concepts have emerged that demonstrate the role of dysregulation of alternative complement pathway in evolution of MPGN that led to classifying into two subgroups,immune complex mediated MPGN and complement-mediated MPGN.The latter comprises of the dense deposit disease and the C3 GN disease.De novo C3 disease is rather rare.Prognosis of de novo diseases varies with each type and their management continues to be empirical to a large extent.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号